List view / Grid view
10 December 2015 | By Victoria White
Faster-acting insulin aspar is an investigational mealtime insulin developed by Novo Nordisk for the control of blood sugar levels in adults with type 1 and type 2 diabetes...
4 December 2015 | By Victoria White
Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes...
2 December 2015 | By Victoria White
Novo Nordisk has released new data that shows Victoza (liraglutide) provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to sodium-glucose cotransporter 2 inhibitors...
16 November 2015 | By Victoria White
New research shows socio-cultural factors including time pressure, commuting time and where you live play significant roles in diabetes vulnerability...
5 November 2015 | By Victoria White
Results from the study highlight a general lack of understanding of obesity as a disease and its impact on the body...
4 November 2015 | By Victoria White
Saxenda in combination with reduced-calorie diet and increased physical activity also delayed the onset of type 2 diabetes in the three-year extension trial...
25 September 2015 | By Victoria White
The trial investigated the efficacy and safety of semaglutide compared with exenatide in 813 people with type 2 diabetes...
24 September 2015 | By
The project is expected to last five years and represents a Novo Nordisk investment of approximately 70 million euros...
17 September 2015 | By Victoria White
The DUAL V trial evaluated the efficacy and safety of Xultophy compared to insulin glargine U100 in adults with type 2 diabetes...
16 September 2015 | By Victoria White
Results from a new study showed different perceptions of control among physicians and patients that may lead to suboptimal type 2 diabetes management...
16 September 2015 | By Victoria White
Findings from the LIRA-LIXI trial have demonstrated a significantly greater reduction in blood sugar for liraglutide compared to lixisenatide in type 2 diabetes...
15 September 2015 | By Victoria White
Data show that Tresiba U200 significantly lowers both rates of hypoglycaemia and mean fasting blood glucose compared to insulin glargine U100 in patients with type 2 diabetes...
15 September 2015 | By Victoria White
Not only are Saxenda 'early responders' more likely to achieve greater weight loss, they are also more likely to experience greater improvements in cardiometabolic risk factors...
25 August 2015 | By Victoria White
Novo Nordisk has announced headline results from the final Phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes...
20 July 2015 | By Victoria White
The FDA has approved Novo Nordisk’s FlexPro PenMate, designed for users of Norditropin FlexPro pens who dislike needles and prefer them to be hidden...
